W
Weijian Guo
Researcher at Fudan University
Publications - 91
Citations - 2561
Weijian Guo is an academic researcher from Fudan University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 20, co-authored 76 publications receiving 1586 citations. Previous affiliations of Weijian Guo include Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li,Shukui Qin,Jianming Xu,Weijian Guo,Jianping Xiong,Yuxian Bai,Guo-ping Sun,Yan Yang,Liwei Wang,Nong Xu,Ying Cheng,Zhehai Wang,Leizhen Zheng,M. Tao,Xiao-Dong Zhu,Dongmei Ji,Xin Liu,Hao Yu +17 more
TL;DR: Apatinib showed improved PFS and OS in heavily pretreated patients with mGC who had experienced treatment failure with two or more chemotherapy regimens, and this trial investigated the safety and efficacy of apatinib, an inhibitor of vascular endothelial growth factor receptor, as a treatment option.
Journal ArticleDOI
EZH2: a novel target for cancer treatment.
Ran Duan,Wenfang Du,Weijian Guo +2 more
TL;DR: The structure and action modes of EZH2 are summarized, focusing on up-to-date findings regarding the role of E zeste homolog 2 in cancer initiation, progression, metastasis, metabolism, drug resistance, and immunity regulation.
Journal ArticleDOI
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
TL;DR: The molecular functions of EZH2 are discussed, recent findings regarding the physiological functions and related regulation of E zeste homolog 2 in cancer pathogenesis are highlighted, and the emerging roles of EzH2 in tumor immunity are summarized.
Journal ArticleDOI
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Jin Li,Jin Li,Shukui Qin,Rui-Hua Xu,Lin Shen,Jianming Xu,Yuxian Bai,Lei Yang,Yanhong Deng,Zhen Dong Chen,Haijun Zhong,Hongming Pan,Weijian Guo,Yongqian Shu,Ying Yuan,Jianfeng Zhou,Nong Xu,Tianshu Liu,Dong Ma,Changping Wu,Ying Cheng,Donghui Chen,Wei Li,Sanyuan Sun,Zhuang Yu,Peiguo Cao,Haihui Chen,Jiejun Wang,Shubin Wang,Hongbing Wang,Songhua Fan,Ye Hua,Weiguo Su +32 more
TL;DR: Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival.
Journal ArticleDOI
The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter
Lu Gan,Midie Xu,Rui-Xi Hua,Cong Tan,Jieyun Zhang,Yiwei Gong,Zhenhua Wu,Weiwei Weng,Weiqi Sheng,Weijian Guo +9 more
TL;DR: Ezh2 has a central role in regulating diverse aspects of the pathogenesis of GC in part by involving PTEN/Akt signaling, indicating that it could be an independent prognostic factor and potential therapeutic target.